| Display title | Chemistry:THJ-2201 |
| Default sort key | THJ-2201 |
| Page length (in bytes) | 6,631 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 39404 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>QCDvac |
| Date of page creation | 00:56, 6 February 2024 |
| Latest editor | imported>QCDvac |
| Date of latest edit | 00:56, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.
It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole. |
